Growing List of Targeted Therapies for Patients With mUC

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and of Urology at Yale School of Medicine, and co-leader, Cancer Signaling Networks, Yale Cancer Center, discusses the targeted therapies that have shown encouraging results in patients with metastatic urothelial cancer (mUC).

The field have a few FDA-approved therapies, explains Petrylak, and many therapies are being assessed in clinical trials. The FDA approved the agents include antibody drug conjugates (ADCs), and FGFR inhibitors.

Transcription:

0:07 | So, there are number of targeted therapies that are being evaluated in your field, as we know. Enfortunmab vedotin [Padcev] is FDA approved for those patients who are either platinum eligible and received prior checkpoint or other treatment, as well as those patients who've received 1 chemotherapy and at least 1 chemotherapy, and also received a checkpoint. And as we know, enfortumab is a targeted agent that targets Dectin-4 for and that's almost ubiquitously expressed in metastatic specimens.

0:37 | Similarly, sacituzumab govitecan [Trodelvy] is another targeted therapy that recognizes Trop-2, which is an antigen that's expressed in a number of different tumor types. It's actually FDA approved in breast cancer but has activity in metastatic urothelial carcinoma and is also FDA approved on the accelerated basis for those patients. Erdafitinib [Balversa]is an FGFR3 targeted agent that's approved in those patients who have that mutation and has about a 40% response rate.

1:06 | There are the investigational studies looking at HER2-neu targeted ADCs as well as other targets for the treatment of urothelial cancer.